F
Frank J. Taddeo
Researcher at Merck & Co.
Publications - 30
Citations - 10670
Frank J. Taddeo is an academic researcher from Merck & Co.. The author has contributed to research in topics: Cervical intraepithelial neoplasia & Cervical cancer. The author has an hindex of 23, co-authored 30 publications receiving 10260 citations. Previous affiliations of Frank J. Taddeo include United States Military Academy & Ludwig Institute for Cancer Research.
Papers
More filters
Journal ArticleDOI
Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions
Luisa L. Villa,Gonzalo Perez,Susanne K. Kjaer,Jorma Paavonen,Matti Lehtinen,Nubia Muñoz,Kristjan Sigurdsson,Mauricio Hernández-Ávila,Finn Egil Skjeldestad,Steinar Thoresen,Patricia J. Garcia,Slawomir Majewski,Joakim Dillner,Sven Eric Olsson,Hseon Tay Eng,F. Xavier Bosch,Kevin A. Ault,Darron R. Brown,Daron G. Ferris,Laura A. Koutsky,Robert J. Kurman,Evan R. Myers,Eliav Barr,John W. Boslego,Janine T. Bryan,Mark T. Esser,Christine K. Gause,Teresa M. Hesley,Lisa Lupinacci,Heather L. Sings,Frank J. Taddeo,Annemarie R. Thornton +31 more
TL;DR: In young women who had not been previously infected with HPV-16 or HPV-18, those in the vaccine group had a significantly lower occurrence of high-grade cervical intraepithelial neoplasia related to HPV- 16 or HPV -18 than did those inThe placebo group.
Journal ArticleDOI
Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases.
Suzanne M. Garland,Suzanne M. Garland,Mauricio Hernández-Ávila,Cosette M. Wheeler,Gonzalo Perez,Diane M. Harper,Sepp Leodolter,Grace W.K. Tang,Daron G. Ferris,Marc Steben,Janine T. Bryan,Frank J. Taddeo,Radha Railkar,Mark T. Esser,Heather L. Sings,Micki Nelson,John W. Boslego,Carlos Sattler,Eliav Barr,Laura A. Koutsky +19 more
TL;DR: The quadrivalent vaccine significantly reduced the incidence of HPV-associated anogenital diseases in young women in this randomized, placebo-controlled, doubleblind trial.
Journal ArticleDOI
Prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in young women: a randomised double-blind placebo-controlled multicentre phase II efficacy trial
Luisa L. Villa,Ronaldo L.R. Costa,Carlos Alberto Petta,Rosires Pereira de Andrade,Kevin A. Ault,Anna R. Giuliano,Cosette M. Wheeler,Laura A. Koutsky,Christian Malm,Matti Lehtinen,Finn Egil Skjeldestad,Sven Eric Olsson,Margareta Steinwall,Darron R. Brown,Robert J. Kurman,Brigitte M. Ronnett,Mark H. Stoler,Alex Ferenczy,Diane M. Harper,Gretchen M. Tamms,Jimmy Yu,Lisa Lupinacci,Radha Railkar,Frank J. Taddeo,Kathrin U. Jansen,Mark T. Esser,Heather L. Sings,Alfred Saah,Eliav Barr +28 more
TL;DR: In this paper, a double-blind placebo-controlled phase II study was done to assess the efficacy of a prophylactic quadrivalent vaccine targeting the human papillomavirus (HPV) types associated with 70% of cervical cancers (types 16 and 18) and with 90% of genital warts (types 6 and 11).
Journal ArticleDOI
High sustained efficacy of a prophylactic quadrivalent human papillomavirus types 6/11/16/18 L1 virus-like particle vaccine through 5 years of follow-up
Luisa L. Villa,Ronaldo L.R. Costa,Carlos Alberto Petta,Rosires Pereira de Andrade,Jorma Paavonen,O-E Iversen,S-E Olsson,J. Hoye,Margareta Steinwall,G. Riis-Johannessen,A. Andersson-Ellstrom,Kristina Elfgren,G. Von Krogh,Matti Lehtinen,Christian Malm,Gretchen M. Tamms,Katherine E.D. Giacoletti,Lisa Lupinacci,Radha Railkar,Frank J. Taddeo,Janine T. Bryan,Mark T. Esser,Heather L. Sings,Alfred Saah,Eliav Barr +24 more
TL;DR: A prophylactic quadrivalent HPV vaccine was effective through 5 years for prevention of persistent infection and disease caused by HPV 6/11/16/18, and this duration supports vaccination of adolescents and young adults.
Journal ArticleDOI
The Impact of Quadrivalent Human Papillomavirus (HPV; Types 6, 11, 16, and 18) L1 Virus-Like Particle Vaccine on Infection and Disease Due to Oncogenic Nonvaccine HPV Types in Generally HPV-Naive Women Aged 16–26 Years
Darron R. Brown,Susanne K. Kjaer,Kristjan Sigurdsson,Ole-Erik Iversen,Mauricio Hernández-Ávila,Cosette M. Wheeler,Gonzalo L. Pérez,Laura A. Koutsky,Eng Tay,Patricia J. Garcia,Kevin A. Ault,Suzanne M. Garland,Sepp Leodolter,Sven-Eric Olsson,Grace W.K. Tang,Daron G. Ferris,Jorma Paavonen,Marc Steben,F. Xavier Bosch,Joakim Dillner,Elmar A. Joura,Robert J. Kurman,Slawomir Majewski,N. Munoz,Evan R. Myers,Luisa L. Villa,Frank J. Taddeo,Christine C. Roberts,Amha Tadesse,Janine Bryan,Lisa Lupinacci,Katherine E. D. Giacoletti,Heather L. Sings,Margaret James,Teresa M. Hesley,Eliav Barr +35 more
TL;DR: These cross-protection results complement the vaccine's prophylactic efficacy against disease associated with HPV-6, -11, -16, and -18 and are needed to fully ascertain the population-based impact and public health significance of these findings.